Literature DB >> 3755310

Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome.

J J Seidenfeld, D F Pohl, R C Bell, G D Harris, W G Johanson.   

Abstract

Bacterial infection in the adult respiratory distress syndrome (ARDS) is associated with the occurrence of multiple organ failures and death. We studied 108 infections in 129 patients with ARDS and evaluated the organisms responsible, the body sites involved, and the outcomes of therapy. Gram-negative bacilli represented 57% of the microbial pathogens and gram-positive cocci 36%. Only 7% of infections were caused by other organisms (fungi, viruses, Pneumocystis, Legionella). Gram-negative organisms were more common in the lung, abdomen, and pleura. Bacteremia was more common in abdominal infections (11 of 17, 67%) than in infections at other sites (18 of 65, 28%), (p less than 0.01); ;9 patients were bacteremic from clinically undetected sites. Ten of 17 (59%) patients with abdominal infections survived compared with 7 of 56 (13%) patients with lung infections (p less than 0.001). A retrospective review of in vitro organism susceptibility and the antibiotics administered revealed that the patients who received adequate antibiotic therapy did not have a higher survival rate (20 of 69, 29%) than those who received inadequate antibiotic therapy (3 of 13, 23%). These data suggest that further investigation of infections in patients with ARDS is required and that emphasis should be placed on pathogenesis, prevention, and host responses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755310     DOI: 10.1164/arrd.1986.134.1.12

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  33 in total

Review 1.  Acute respiratory distress syndrome and nosocomial pneumonia.

Authors:  T T Bauer; A Torres
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

2.  Pulmonary Infections in Ventilated Patients: Diagnostic and Therapeutic Options.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 3.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

Review 4.  The adult respiratory distress syndrome. New insights into diagnosis, pathophysiology, and treatment.

Authors:  M A Matthay
Journal:  West J Med       Date:  1989-02

Review 5.  Evaluation of the available invasive and non-invasive techniques for diagnosing nosocomial pneumonias in mechanically ventilated patients.

Authors:  A Torres; J González; M Ferrer
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 6.  Endothelial modification of pulmonary vascular tone.

Authors:  N P Curzen; K B Jourdan; J A Mitchell
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 7.  Prevention and therapy of the adult respiratory distress syndrome.

Authors:  B Temmesfeld-Wollbrück; D Walmrath; F Grimminger; W Seeger
Journal:  Lung       Date:  1995       Impact factor: 2.584

8.  The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations.

Authors:  P Krafft; P Fridrich; T Pernerstorfer; R D Fitzgerald; D Koc; B Schneider; A F Hammerle; H Steltzer
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

9.  Nosocomial bacteremia in a medical-surgical intensive care unit: epidemiologic characteristics and factors influencing mortality in 111 episodes.

Authors:  J Rello; M Ricart; B Mirelis; E Quintana; M Gurgui; A Net; G Prats
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

10.  Effects of dobutamine on oxygen transport and consumption in the adult respiratory distress syndrome.

Authors:  S L Krachman; R F Lodato; R Morice; G Gutierrez; D R Dantzker
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.